Quick Answer
Axsome Therapeutics, Inc. reported Long Term Debt of $117.75 million for the year ending 2025.
- Axsome Therapeutics, Inc. showed a decrease of -34.8% in Long Term Debt from 2024 to 2025.
- This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $8.78 million | Q2 2017: $8.08 million | Q3 2017: $7.38 million | Q1 2018: $5.93 million | Q2 2018: $5.19 million | Q3 2018: $4.44 million | Q1 2019: $18.82 million | Q2 2019: $17.42 million | Q3 2019: $19.11 million | Q1 2020: $15.54 million | Q2 2020: $13.74 million | Q3 2020: $48.03 million | Q1 2021: $48.60 million | Q2 2021: $48.88 million | Q3 2021: $49.17 million | Q1 2022: $49.31 million | Q2 2022: $93.46 million | Q3 2022: $93.91 million | Q1 2023: $147.62 million | Q2 2023: $176.82 million | Q3 2023: $177.45 million | Q1 2024: $178.69 million | Q2 2024: $179.33 million | Q3 2024: $180.00 million | Q1 2025: $181.38 million | Q2 2025: $117.54 million | Q3 2025: $117.64 million.
- Over the full 10 years of available data (2016 to 2025), Axsome Therapeutics, Inc.'s Long Term Debt has grown by 1,143.3%.
- Historical annual values: Fiscal year 2025: $117.75 million | Fiscal year 2024: $180.71 million | Fiscal year 2023: $178.07 million | Fiscal year 2022: $94.26 million | Fiscal year 2021: $49.09 million | Fiscal year 2020: $48.32 million | Fiscal year 2019: $17.33 million | Fiscal year 2018: $3.62 million | Fiscal year 2017: $6.66 million | Fiscal year 2016: $9.47 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: